Kemia nuclear bodies. J Virol. 2015;89(17):8922?1. 62. Yin Q, Flemington EK. siRNAs against
Kemia nuclear bodies. J Virol. 2015;89(17):8922?1. 62. Yin Q, Flemington EK. siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells. Virology. 2006;346(2):385?3.Yin et al. Virology Journal (2017) 14:Page 12 of63. Yin Q, Wang X, McBride J, Fewell C, Flemington E. B-cell receptor activation induces BIC/miR-155 expression through a conserved AP-1 element. J Biol Chem. 2008;283(5):2654?2. 64. Geoffroy MC, Jaffray EG, Walker KJ, Hay RT. Arsenic-induced SUMOdependent recruitment of RNF4 into PML nuclear bodies. Mol Biol Cell. 2010;21(23):4227?9. 65. Shimizu N, Tanabe-Tochikura A, Kuroiwa Y, Takada K. Isolation of EpsteinBarr virus (EBV)-negative cell clones from the EBV-positive Burkitt’s lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. J Virol. 1994;68(9):6069?3. 66. De Leo A, Arena G, Stecca C, Raciti M, Mattia E. Resveratrol inhibits proliferation and survival of Epstein Barr virus-infected Burkitt’s lymphoma cells depending on viral latency program. Mol Cancer Res. 2011;9(10):1346?5. 67. Liu S, Li H, Chen L, Yang L, Li L, Tao Y, et al. (-)-Epigallocatechin-3-gallate inhibition of Epstein-Barr virus spontaneous lytic infection involves ERK1/2 and PI3-K/Akt signaling in EBV-positive cells. Carcinogenesis. 2013;34(3):627?7. 68. Geser A, de The G, Lenoir G, Day NE, Williams EH. Final case reporting from the Ugandan prospective study of the relationship between EBV and Burkitt’s lymphoma. Int J Cancer. 1982;29(4):397?00. 69. Yuan J, Cahir-McFarland E, Zhao B, Kieff E. Virus and cell RNAs expressed during Epstein-Barr virus replication. J Virol. 2006;80(5):2548?5. 70. Webster-Cyriaque J, Middeldorp J, Raab-Traub N. Hairy leukoplakia: an unusual combination of transforming and permissive Epstein-Barr virus infections. J Virol. 2000;74(16):7610?. 71. Yin Q, Wang X, Roberts C, Flemington EK, Lasky JA. Methylation status and AP1 elements are involved in EBV-mediated miR-155 expression in EBV positive lymphoma cells. Virology. 2016;494:158?7. 72. Meng Q, Hagemeier SR, Fingeroth JD, Gershburg E, Pagano JS, Kenney SC. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and Avasimibe manufacturer acyclovir inhibition of lytic viral production. J Virol. 2010;84(9):4534?2. 73. Keever-Taylor CA, Behn B, Konings S, Orentas R, Davies B, Margolis D. Suppression of EBV release from irradiated B lymphoblastoid cell-lines: superior activity of ganciclovir compared with acyclovir. Cytotherapy. 2003;5(4):323?5. 74. Klein G. Role of EBV and Ig/myc translocation in Burkitt lymphoma. Antibiot Chemother. 1994;46:110?. 75. Flemington EK, Lytle JP, Cayrol C, Borras AM, Speck SH. DNA-bindingdefective mutants of the Epstein-Barr virus lytic switch activator Zta transactivate with altered specificities. Mol Cell Biol. 1994;14(5):3041?2. 76. Liu P, Speck SH. Synergistic autoactivation of the Epstein-Barr virus immediate-early BRLF1 promoter by Rta and Zta. Virology. 2003;310(2):199?06. 77. Yang PW, Chang SS, Tsai CH, Chao YH, Chen MR. Effect of PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28212752 phosphorylation on the transactivation activity of Epstein-Barr virus BMRF1, a major target of the viral BGLF4 kinase. J Gen Virol. 2008;89(Pt 4):884?5. 78. Rennekamp AJ, Lieberman PM. Initiation of Epstein-Barr virus lytic replication requires transcription and the formation of a stable RNA-DNA hybrid molecule at OriLyt. J Virol. 2011;85(6):2837?0. 79. Busch K, Keller T,.
